AstraZeneca lung and breast cancer data at WCLC and ESMO 2021 underscore ambition to revolutionise outcomes for patients
- Date 3 Sep 2021
Enhertu demonstrates transformative progression-free survival in HER2-positive metastatic breast cancer; data in lung and gastric cancers show strong efficacy across HER2-targetable tumours.
Multiple trials reinforce the efficacy of Imfinzi combinations, including with novel immunotherapies, for lung cancer patients across settings
AstraZeneca will present new data across its diverse portfolio of cancer medicines at the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) Congress 2021.
You might also be interested in these articles
Cambridge Science Centre Welcomes Rebecca Porter as New CEO
Wed 11 Dec 2024
Technology
Answer the call for speakers & start-ups for CW's International Conference
None
Thu 7 Nov 2024
CW (Cambridge Wireless Ltd)
Technology
Celebrating the Cambridge Tech Week Innovation Alley Award Winners
None
Wed 2 Oct 2024
CW (Cambridge Wireless Ltd)